This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line…
- Investigator
- Dennie Jones
- Status
- Accepting Candidates
- Ages
- 18 Years - N/A
- Sexes
- All